[Insert Table 2]
On the other hand, seven studies were included to calculate pooled relative risk for severe/critical disease [11,13,14,18-21] in COVID-19 patients with hypertension, exposed or unexposed to ACEIs/ARBs (Table 3 ). The studies from Feng et al. [15] and Peng et al. [16] did not segregate the patients based on the presence of hypertension and therefore were excluded from our pooled analysis to ensure a uniform cohort of hypertensive patients being analysed. Moreover, Lee et al. [12], Chen et al. [17], and Mehra et al. [22] did not present data on severity by ACEIs/ARBs use and hence were also excluded from the analysis.